Do analysts rate AKBA or INMB?

Akebia Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 326.82%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer AKBA or INMB?

In the previous week, Akebia Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Akebia Therapeutics and 3 mentions for INmune Bio. INmune Bio's average media sentiment score of 1.13 beat Akebia Therapeutics' score of 0.71 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TARA or INMB?

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 587.17%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is TARA or INMB more profitable?

Protara Therapeutics' return on equity of -41.72% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% INmune Bio N/A -82.87% -62.23%

Does the media prefer TARA or INMB?

In the previous week, Protara Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Protara Therapeutics and 3 mentions for INmune Bio. Protara Therapeutics' average media sentiment score of 1.16 beat INmune Bio's score of 1.13 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ORGO or INMB?

Organogenesis currently has a consensus price target of $4.33, suggesting a potential upside of 149.04%. Given Organogenesis' higher possible upside, equities analysts plainly believe Organogenesis is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings and valuation, ORGO or INMB?

Organogenesis has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.40 $37.03M -$0.86 N/A INmune Bio $50K 1,293.15 -$45.93M -$0.67 N/A

Is ORGO or INMB more profitable?

INmune Bio has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -19.94% -23.89% -11.13% INmune Bio N/A -82.87% -62.23%

Does the media prefer ORGO or INMB?

In the previous week, INmune Bio had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Organogenesis. INmune Bio's average media sentiment score of 1.13 beat Organogenesis' score of 1.07 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INMB or GALT?

Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 173.63%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Galectin Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INMB or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Galectin Therapeutics N/A N/A -176.83%

Does the media favor INMB or GALT?

In the previous week, INmune Bio and INmune Bio both had 3 articles in the media. INmune Bio's average media sentiment score of 1.13 beat Galectin Therapeutics' score of 0.82 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INMB or CGEN?

Compugen has a consensus target price of $5.00, suggesting a potential upside of 92.31%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Compugen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has better earnings & valuation, INMB or CGEN?

Compugen has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,293.15 -$45.93M -$0.67 N/A Compugen $72.76M 3.38 $35.34M $0.38 6.84

Is INMB or CGEN more profitable?

Compugen has a net margin of 47.56% compared to INmune Bio's net margin of 0.00%. Compugen's return on equity of 42.57% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Compugen 47.56% 42.57% 26.13%

Does the media refer more to INMB or CGEN?

In the previous week, INmune Bio had 1 more articles in the media than Compugen. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Compugen. Compugen's average media sentiment score of 1.47 beat INmune Bio's score of 1.13 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

INmune Bio (INMB) Competitors

$2.33 -0.07 (-2.92%)

As of 08/28/2026 04:00 PM Eastern

Compare

INMB vs. AKBA, TARA, ORGO, GALT, and CGEN

Should you buy INmune Bio stock or one of its competitors? INmune Bio's main competitors and comparable companies include Akebia Therapeutics (AKBA), Protara Therapeutics (TARA), Organogenesis (ORGO), Galectin Therapeutics (GALT), and Compugen (CGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does INmune Bio compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

INmune Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. INmune Bio's return on equity of -82.87% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
INmune Bio	N/A	-82.87%	-62.23%

Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Akebia Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 326.82%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Akebia Therapeutics has higher revenue and earnings than INmune Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.03	-$5.34M	-$0.11	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Akebia Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Akebia Therapeutics and 3 mentions for INmune Bio. INmune Bio's average media sentiment score of 1.13 beat Akebia Therapeutics' score of 0.71 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

INmune Bio beats Akebia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does INmune Bio compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Protara Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

INmune Bio has higher revenue and earnings than Protara Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

In the previous week, Protara Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for Protara Therapeutics and 3 mentions for INmune Bio. Protara Therapeutics' average media sentiment score of 1.16 beat INmune Bio's score of 1.13 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics' return on equity of -41.72% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
INmune Bio	N/A	-82.87%	-62.23%

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 587.17%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Protara Therapeutics beats INmune Bio on 10 of the 15 factors compared between the two stocks.

How does INmune Bio compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Organogenesis has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Organogenesis currently has a consensus price target of $4.33, suggesting a potential upside of 149.04%. Given Organogenesis' higher possible upside, equities analysts plainly believe Organogenesis is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 21.4% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, INmune Bio had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Organogenesis. INmune Bio's average media sentiment score of 1.13 beat Organogenesis' score of 1.07 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.40	$37.03M	-$0.86	N/A
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A

INmune Bio has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
INmune Bio	N/A	-82.87%	-62.23%

Summary

Organogenesis and INmune Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Galectin Therapeutics?

INmune Bio (NASDAQ:INMB) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 173.63%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has lower revenue, but higher earnings than INmune Bio. Galectin Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

In the previous week, INmune Bio and INmune Bio both had 3 articles in the media. INmune Bio's average media sentiment score of 1.13 beat Galectin Therapeutics' score of 0.82 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Galectin Therapeutics	N/A	N/A	-176.83%

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

INmune Bio beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Compugen?

INmune Bio (NASDAQ:INMB) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Compugen has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market.

Compugen has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,293.15	-$45.93M	-$0.67	N/A
Compugen	$72.76M	3.38	$35.34M	$0.38	6.84

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, INmune Bio had 1 more articles in the media than Compugen. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Compugen. Compugen's average media sentiment score of 1.47 beat INmune Bio's score of 1.13 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a consensus target price of $5.00, suggesting a potential upside of 92.31%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Compugen has a net margin of 47.56% compared to INmune Bio's net margin of 0.00%. Compugen's return on equity of 42.57% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Compugen	47.56%	42.57%	26.13%

Summary

Compugen beats INmune Bio on 12 of the 16 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.67M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.48	11.62	273.16	25.42
Price / Sales	1,293.15	1,380.91	631.89	104.53
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.65	16.92	11.08	6.36
Net Income	-$45.93M	-$22.74M	$3.48B	$349.79M
7 Day Performance	0.43%	-0.31%	0.13%	-0.80%
1 Month Performance	31.64%	9.80%	7.08%	4.13%
1 Year Performance	14.78%	55.66%	24.67%	15.17%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	0.7815 of 5 stars	$2.33 -2.9%	N/A	+14.8%	$64.67M	$50K	N/A	10	Positive News
AKBA Akebia Therapeutics	2.3351 of 5 stars	$0.84 -2.6%	$3.75 +347.5%	-72.0%	$232.77M	$236.20M	N/A	430
TARA Protara Therapeutics	1.9435 of 5 stars	$3.93 -1.4%	$26.25 +568.8%	+22.4%	$231.95M	N/A	N/A	30	News Coverage Positive News
ORGO Organogenesis	1.8271 of 5 stars	$1.77 +2.6%	$4.33 +145.5%	-66.2%	$228.40M	$454.61M	N/A	950
GALT Galectin Therapeutics	1.826 of 5 stars	$3.38 -3.7%	$11.00 +225.4%	-6.1%	$222.61M	N/A	N/A	9	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. AKBA, TARA, ORGO, GALT, and CGEN

How does INmune Bio compare to Akebia Therapeutics?

Summary

How does INmune Bio compare to Protara Therapeutics?

Summary

How does INmune Bio compare to Organogenesis?

Summary

How does INmune Bio compare to Galectin Therapeutics?

Summary

How does INmune Bio compare to Compugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. AKBA, TARA, ORGO, GALT, and CGEN

How does INmune Bio compare to Akebia Therapeutics?

Is AKBA or INMB more profitable?

Which has more risk and volatility, AKBA or INMB?

Do analysts rate AKBA or INMB?

Which has better valuation and earnings, AKBA or INMB?

Do insiders & institutionals believe in AKBA or INMB?

Does the media prefer AKBA or INMB?

Summary

How does INmune Bio compare to Protara Therapeutics?

Which has more volatility & risk, TARA or INMB?

Which has stronger earnings & valuation, TARA or INMB?

Does the media prefer TARA or INMB?

Is TARA or INMB more profitable?

Do insiders & institutionals hold more shares of TARA or INMB?

Do analysts rate TARA or INMB?

Summary

How does INmune Bio compare to Organogenesis?

Which has more volatility & risk, ORGO or INMB?

Do analysts prefer ORGO or INMB?

Do insiders and institutionals have more ownership in ORGO or INMB?

Does the media prefer ORGO or INMB?

Which has better earnings and valuation, ORGO or INMB?

Is ORGO or INMB more profitable?

Summary

How does INmune Bio compare to Galectin Therapeutics?

Which has more volatility & risk, INMB or GALT?

Do analysts recommend INMB or GALT?

Which has preferable valuation & earnings, INMB or GALT?

Does the media favor INMB or GALT?

Is INMB or GALT more profitable?

Do insiders & institutionals believe in INMB or GALT?

Summary

How does INmune Bio compare to Compugen?

Which has more risk & volatility, INMB or CGEN?

Which has better earnings & valuation, INMB or CGEN?

Do institutionals and insiders have more ownership in INMB or CGEN?

Does the media refer more to INMB or CGEN?

Do analysts prefer INMB or CGEN?

Is INMB or CGEN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools